Vardenafil improves the key variables that determine sexual satisfaction in men with coexisting diabetes and erectile dysfunction (ED). Irwin Goldstein, MD, from Boston University, in Boston, Massachusetts, presented results at the 63rd Scientific Sessions of the American Diabetes Association. 452 men with type 1 or 2 diabetes and ED for at least 6 months who were randomized to 12 weeks of treatment with placebo, vardenafil 10 mg, or vardenafil 20 mg. Individuals who had sustained a significant cardiovascular event in the 6 months prior to the study or who had active proliferative retinopathy or retinitis pigmentosa were excluded from the trial The mean per-patient success rate for vaginal penetration and for sexual intercourse was 64% and 54%, respectively, for the 20 mg dose. Overall, 72% of patients who completed the study and were treated with the 20 mg dose reported improved erections. Vardenafil 20 mg significantly improved the level of satisfaction with erection hardness, satisfaction with the sexual experience, ability to ejaculate, domains of intercourse satisfaction and orgasmic function on the International Index of Erectile Dysfunction (IIEF). Adverse events were those that typically occur with PDE5 inhibitors, and included headache, flushing, rhinitis and sinusitis. “In this challenging population of men with ED and diabetes, vardenafil improved key aspects of the sexual experience important to quality of life,” Dr. Goldstein said. “In fact, rates of satisfaction and erection hardness were three times greater with the 20 mg dose of vardenafil compared to placebo.” Overall, about 50% of men develop erectile dysfunction within 10 years of being diagnosed with diabetes, he added. This study was carried out at 47 sites in the US and Canada. [Study title: Vardenafil (Levitra) Improved Satisfaction with Erectile Hardness, Orgasmic Function and Sexual Experience in Men with Diabetes with Erectile Dysfunction. Abstract 68] ================================ Did YOU KNOW: In 1995, 62% ofpeople with diabetes in the world lived in developing countries. By 2025 this is predicted to rise to more than 75% (IDF Diabetes Voice May 2003).